Get the Stockscreener App
5.10
13.33%
0.60
After Hours:
5.24
0.14
+2.75%
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $5.10, with a volume of 9.21M.
It is up +13.33% in the last 24 hours and down -27.56% over the past month.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
See More
Previous Close:
$4.50
Open:
$4.51
24h Volume:
9.21M
Relative Volume:
3.50
Market Cap:
$1.60B
Revenue:
$9.47B
Net Income/Loss:
$-178.00M
P/E Ratio:
-10.62
EPS:
-0.48
Net Cash Flow:
$1.01B
1W Performance:
+16.70%
1M Performance:
-27.56%
6M Performance:
-39.00%
1Y Performance:
-41.11%
1-Day Range:
$4.51
$5.265
1-Week Range:
$4.25
$5.265
52-Week Range:
$3.96
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
5.10 | 1.60B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Bausch Health Provides Update on Solta Medical - marketscreener.com
U.S. District Court Rules in Favor of Bausch Health and FDA in XIFAXAN Case - TipRanks
Bausch Health shares jump on favorable court ruling - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Major Legal Win: How Bausch Health's Court Victory Protects Billion-Dollar XIFAXAN Franchise Until 2028 - Stock Titan
Fitch raises Bausch Health rating to CCC+ amid refinancing - Investing.com
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg
Topical Drug Delivery Market Set to Witness Significant Growth - openPR.com
Verteporfin Market Generated Opportunities, Future Scope - openPR.com
Bausch Health Companies IncAdopts Shareholder Rights PlanSEC Filing - marketscreener.com
Scar Treatment Market Set to Witness Significant Growth - openPR.com
Bausch Health Adopts Shareholder Rights Plan to Ensure Fair Treatment - TipRanks
Bausch Health Announces Adoption of Shareholder Rights Plan - The Joplin Globe
Bausch Health's New Poison Pill Defense: Key Details of Shareholder Protection Strategy - Stock Titan
The most oversold and overbought stocks on the TSX - The Globe and Mail
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin - marketscreener.com
Intraocular Lens Market Overall Study Report 2025-2032 | Bausch - openPR.com
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program - ACCESS Newswire
New $10K Scholarship Program Empowers Students Affected by Skin Conditions - Stock Titan
Bausch Health secures intent for acne treatment coverage By Investing.com - Investing.com South Africa
Atopic Dermatitis Pipeline 2025: Therapies Under - openPR.com
Bausch Health signs LOI with pan-Canadian Pharmaceutical Alliance for CABTREO - TipRanks
Bausch Health Canada signs Cabtreo public drug plan coverage letter of intent - TipRanks
Bausch Health secures intent for acne treatment coverage - Investing.com Australia
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris - Yahoo Finance
Bausch Health Companies Unit Entered Into A New Senior Secured Credit Agreement - MarketScreener
Ophthalmology Market Report 2025 | Industry to Reach US$93.7 Billion by 2030 | Emerging Research Activities of Ophthalmology Treatments and Availability of Grants Present Business Opportunities - GlobeNewswire Inc.
Bausch Health Misses Revenue Estimates, RBC Analysts React - Finimize
Bausch Health Faces Revenue Miss And Price Target Cut - Finimize
Alex Meruelo Reports 9.99% Stake In Bausch Health Companies Inc As Of March 31SEC Filing - MarketScreener
Sector Update: Health Care Stocks Slipping in Late Afternoon Trading - MarketScreener
Bausch Health Faces Challenges Amid Price Target Downgrade - Evrim Ağacı
Bausch Health stock target cut to $8.50 by RBC Capital - Investing.com South Africa
RBC Previews Bausch Health's Q1 - MarketScreener
RBC Capital Adjusts PT on Bausch Health Companies to $8.50 From $9, Keeps Sector Perform Rating - MarketScreener
Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity - Seeking Alpha
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bausch Health Companies Becomes Oversold (BHC) - Nasdaq
Eye Health Supplements Market Growth in Future Scope 2025-2032 | - openPR.com
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month - guardonline.com
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHC - AsiaOne
Oral Mucositis Market reached US$ 1.62 billion in 2023 and - openPR.com
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):